[1]Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: A population-based study. J Clin Gastroenterol, 2015, 49(8): 690-696. [2]Yamada S, Morine Y, Imura S, et al. Liver regeneration after splenectomy in patients with liver cirrhosis. Hepatol Res, 2016, 46(5): 443-449. [3]Dong F, Luo SH, Zheng LJ, et al. Incidence of portal vein thrombosis after splenectomy and its influence on transjugular intrahepatic portosystemic shunt stent patency. World J Clin Cases, 2019, 7(17): 2450-2462. [4]Ushitora Y, Tashiro H, Takahashi S, et al. Splenectomy in chronic hepatic disorders: portal vein thrombosis and improvement of liver function. Dig Surg, 2011, 28(1): 9-14. [5]Boike JR, Flamm SL. Transjugular intrahepatic portosystemic shunts: advances and new uses in patients with chronic liver disease. Clin Liver Dis, 2020, 24(3): 373-388. [6]Valentin N, Korrapati P, Constantino J, et al. The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol, 2018, 30(10): 1187-1193. [7]Yue-Meng W, Li YH, Wu HM, et al. Portal vein thrombosis in patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt: risk factors, warfarin efficacy, and clinical outcomes. Clin Appl Thromb Hemost, 2018, 24(3): 462-470. [8]Buob S, Johnston AN, Webster CR. Portal hypertension: pathophysiology, diagnosis, and treatment. J Vet Intern Med, 2011, 25(2): 169-186. [9]Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol, 2013, 58(3): 593-608. [10] Okuda K, Ohnishi K, Kimura K, et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology, 1985, 89(2): 279-286. [11] Loring LA, Panicek DM, Karpeh MS. Portal system thrombosis after splenectomy for neoplasm or chronic hematologic disorder: is routine surveillance imaging necessary? J Comput Assist Tomogr, 1998, 22(6): 856-860. [12] Zhou JB, Luo BY, Liu CW, et al. Effects of early antiplatelet therapy after splenectomy with gastro-oesophageal devascularization. ANZ J Surg, 2018, 88(10): E725-e729. [13] Jiang GQ, Bai DS, Chen P, et al. Risk factors for portal vein system thrombosis after laparoscopic splenectomy in cirrhotic patients with hypersplenism. J Laparoendosc Adv Surg Tech A, 2016, 26(6): 419-423. [14] Huang D, Tao M, Cao L, et al. Risk factors and anticoagulation effects of portal vein system thrombosis after laparoscopic splenectomy in patients with or without cirrhosis. Surg Laparosc Endosc Percutan Tech A, 2019, 29(6): 498-502. [15] Jiang GQ, Bai DS, Chen P, et al. Predictors of portal vein system thrombosis after laparoscopic splenectomy and azygoportal disconnection: a retrospective cohort study of 75 consecutive patients with 3-months follow-up. Int J Surg, 2016, 30: 143-149. [16] 韩东, 彭经纬, 谢辉晋. 脾切除联合贲门周围血管离断术治疗肝硬化门脉高压症患者预防门静脉血栓形成研究. 实用肝脏病杂志, 2020, 23(5): 409-412 [17] Modaresi Esfeh J, Ansari-Gilani K. Transjugular intrahepatic portosystemic shunt in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol, 2020, 32(6): 762-763. [18] Lyu Y, He C, Wang Z, et al. Association of nonmalignant portal vein thrombosis and outcomes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis. Radiology, 2017, 285(3): 999-1010. [19] Zhang L, Huan H, Tong H, et al. Warfarin prevented de novo portal vein thrombosis after transjugular intrahepatic portosystemic shunt: A retrospective study. Medicine (Baltimore), 2020, 99(2): e18737. [20] Wang JT, Zhao HY, Liu YL. Portal vein thrombosis. Hepatobiliary Pancreat Dis Int, 2005, 4(4): 515-518. |